News

CGeneTech's Class I innovative drug Centagliptin phosphate enters Phase I clinic

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2017-09-15
  • Views:0

(Summary description)China is a major diabetic country with over 100 million diabetic patients, ranking first in the world. CGeneTech Biomedical Technologies (Suzhou) Co., Ltd.'s clinical trial application for a Class I innovative drug, Centagliptin phosphate, for the treatment of type 2 diabetes was approved by the State Food and Drug Administration in May 2017. At present, Centec has entered into an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the Phase I clinical trial of Centagliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycaemia and weight gain, and is cardiovascular protective; at the same time, Chinese patients with type 2 diabetes benefit more from DPP-4 inhibitors because they have more damaged pancreatic beta cells than those in Europe and the US, and one of the features of DPP-4 inhibitors is that they can improve beta cell damage. This has led to the increasing acceptance of DPP-4 inhibitors by doctors in China.

CGeneTech's Class I innovative drug Centagliptin phosphate enters Phase I clinic

(Summary description)China is a major diabetic country with over 100 million diabetic patients, ranking first in the world. CGeneTech Biomedical Technologies (Suzhou) Co., Ltd.'s clinical trial application for a Class I innovative drug, Centagliptin phosphate, for the treatment of type 2 diabetes was approved by the State Food and Drug Administration in May 2017. At present, Centec has entered into an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the Phase I clinical trial of Centagliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycaemia and weight gain, and is cardiovascular protective; at the same time, Chinese patients with type 2 diabetes benefit more from DPP-4 inhibitors because they have more damaged pancreatic beta cells than those in Europe and the US, and one of the features of DPP-4 inhibitors is that they can improve beta cell damage. This has led to the increasing acceptance of DPP-4 inhibitors by doctors in China.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2017-09-15
  • Views:0

  China is a major diabetic country with over 100 million diabetic patients, ranking first in the world. CGeneTech(Suzhou,China)Co.,Ltd's clinical trial application for a Class I innovative drug, Centagliptin phosphate, for the treatment of type 2 diabetes was approved by the State Food and Drug Administration in May 2017. At present, Centec has entered into an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the Phase I clinical trial of Centagliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycaemia and weight gain, and is cardiovascular protective; at the same time, Chinese patients with type 2 diabetes benefit more from DPP-4 inhibitors because they have more damaged pancreatic beta cells than those in Europe and the US, and one of the features of DPP-4 inhibitors is that they can improve beta cell damage. This has led to the increasing acceptance of DPP-4 inhibitors by doctors in China.

 Cetagliptin phosphate is a new diabetes drug developed by the National 12th Five-Year Plan and Jiangsu Province's Science and Technology Support Program. The pre-clinical studies of Cetagliptin phosphate have shown that it is 3-10 times more effective than the world's best drug, Selegiline phosphate (Genovate), and more than 5 times safer than Selegiline phosphate, which is a clear advantage. The successful launch of Cetagliptin phosphate will bring a more affordable, safe and effective drug option to hundreds of millions of Chinese type 2 diabetes patients and will further improve the treatment of type 2 diabetes in China. Centurion will always take independent innovation as the driving force for its development, continue to undertake the mission of developing new drugs for major diseases in China, work closely with academic forces at home and abroad, and actively explore the development of China's pharmaceutical technology industrialisation for the benefit of Chinese patients.

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO